{"id":"W4310566600","doi":"10.1001/jamaoncol.2022.5610","title":"Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases","year":2022,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Aptitude Health; Eisai; National Breast Cancer Foundation; Seagen; G1 Therapeutics; Daiichi-Sankyo; MacroGenics; Silverback Therapeutics; Puma Biotechnology; Medac; Ipsen; OncoSec Medical; Syndax Pharmaceuticals; BioMarin Pharmaceutical; Mylan; Ionis Pharmaceuticals; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Vertex Pharmaceuticals; Foundation Medicine; Genomic Health; Breast Cancer Research Foundation; Jounce Therapeutics; Celgene; Genentech; Veracyte; Amgen; Radius Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Yale University; Sanofi; GlaxoSmithKline; Carrick Therapeutics; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer","keywords":"Capecitabine; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Placebo; Oncology; Breast cancer; Pertuzumab; Cancer; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005315593,0.0002827587,0.0007541502,0.000311913,0.0001109044,0.00001684671,0.0000692821,0.00005067558,0.0002760401],"category_scores_gemma":[0.00006193767,0.0001922696,0.00004911942,0.0004398199,0.0001173421,0.0001347871,0.00004242034,0.0002242774,8.965692e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001278129,"about_ca_system_score_gemma":0.0004633731,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001215194,"about_ca_topic_score_gemma":0.003783721,"domain_scores_codex":[0.9978235,0.0005835888,0.0003858971,0.0004993913,0.0002811832,0.0004263741],"domain_scores_gemma":[0.9985288,0.0008105739,0.0002310212,0.0001779549,0.0001230331,0.0001286205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06097251,0.0130641,0.7169603,0.0002841293,0.00138217,0.0005911545,0.003549921,0.000307211,0.00006379022,0.0008314272,0.002156978,0.1998363],"study_design_scores_gemma":[0.08634218,0.02313877,0.8856732,0.0001758666,0.0006592626,0.000223763,0.001127045,0.0002548317,0.00005056886,0.00006979308,0.002019831,0.0002649215],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845714,0.0002317324,0.0001393122,0.008986842,0.00004495642,0.00402422,0.00182403,0.00002439652,0.0001531337],"genre_scores_gemma":[0.9928613,0.00002148421,0.001995229,0.001158312,0.00001984817,0.003015317,0.0006832056,0.00004865134,0.0001966374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1995714,"threshold_uncertainty_score":0.7840527,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009678729924896167,"score_gpt":0.2817659237388417,"score_spread":0.2720871938139456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}